Far Bahareh Farasati, Saffari Partow Mirzaee, Jafari Razieh Mohammad, Goudarzi Ramin, Dehpour Ahmad Reza, Partoazar Alireza
Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Department of Chemistry, Iran University of Science and Technology, Tehran, Iran.
Drug Res (Stuttg). 2025 Jan;75(1):12-20. doi: 10.1055/a-2419-9616. Epub 2024 Oct 15.
Psoriasis is a chronic skin condition that is associated with persistent inflammation and skin lesions. Topical therapy has been a promising approach to the alleviation of psoriasis through the application of anti-inflammatory agents. Phosphatidylserine (PS) administration has shown anti-inflammatory effects in the trials. Consequently, the objective of this study was to evaluate the effects of topical PS on the potential improvement of an imiquimod (IMQ)-induced psoriasis model. Additionally, cyclosporine A was utilized as a comparative anti-psoriatic agent in our study.
The psoriasis model was established by topically applying IMQ to the dorsal skin of mice once daily for five consecutive days. The efficacy of topical PS was assessed using the Psoriasis Area and Severity Index (PASI) score to evaluate skin lesions. Subsequently, the skin samples were analyzed using Baker's scoring system, Masson's trichrome staining, immunohistochemistry, and real-time PCR analysis.
IMQ-induced plaque-type psoriasis resulted in a significant increase in dermal thickness, hyperkeratosis, PASI score, and inflammatory cytokines at the lesion site. The topical PS and cyclosporine A significantly reduced PASI score and dermal thickness, while also alleviating erythema and scaling when compared to untreated mice. Furthermore, biomolecular assessments revealed that PS significantly inhibited the gene expression of IL-17, IL-23, and TNF-α cytokines in the IMQ-induced lesions.
Topical PS may pointedly alleviate psoriasis through the inhibition of inflammation. The beneficial effects of the PS recommend further investigation in both experimental and clinical studies in the control of skin psoriasis.
银屑病是一种与持续性炎症和皮肤病变相关的慢性皮肤病。局部治疗通过应用抗炎药物一直是缓解银屑病的一种有前景的方法。在试验中，给予磷脂酰丝氨酸（PS）已显示出抗炎作用。因此，本研究的目的是评估局部应用PS对咪喹莫特（IMQ）诱导的银屑病模型潜在改善的效果。此外，在我们的研究中，环孢素A被用作一种对比抗银屑病药物。
通过连续5天每天一次将IMQ局部应用于小鼠背部皮肤建立银屑病模型。使用银屑病面积和严重程度指数（PASI）评分评估局部应用PS的疗效以评估皮肤病变。随后，使用贝克评分系统、Masson三色染色、免疫组织化学和实时PCR分析对皮肤样本进行分析。
IMQ诱导的斑块型银屑病导致病变部位的真皮厚度、角化过度、PASI评分和炎性细胞因子显著增加。与未治疗的小鼠相比，局部应用PS和环孢素A显著降低了PASI评分和真皮厚度，同时也减轻了红斑和脱屑。此外，生物分子评估显示，PS显著抑制了IMQ诱导病变中IL-17、IL-23和TNF-α细胞因子的基因表达。
局部应用PS可能通过抑制炎症明显减轻银屑病。PS的有益作用建议在控制皮肤银屑病的实验和临床研究中进一步研究。
